Search research articles
Contact Us
Filters
Showing results (41-50 of 56) with videos related to
Page
of 6
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer
Yawen Dong, David Pereyra, Vanja Podrascanin, et al.
British Journal of Cancer
|
June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms
T R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
Annals of Surgery
|
June 23, 2025
Development of the Perihilar Cholangiocarcinoma Risk Estimation of Tumor Recurrence After Transplant (PRETREAT) Score
Zhihao Li, Timucin Taner, John E Eaton, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
May 5, 2024
Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
Benjamin J Van Treeck, Maria C Olave, Ryan D Watkins, et al.
The Oncologist
|
December 14, 2024
Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience
Paulina Marell, Ioannis Kournoutas, Jennifer Gile, et al.
Investigational New Drugs
|
August 31, 2021
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
Daniel H Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
May 24, 2024
WITHDRAWN: Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
Benjamin J Van Treeck, Maria C Olave, Ryan D Watkins, et al.
JCO Precision Oncology
|
November 15, 2021
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Jennifer J Gile, Fang-Shu Ou, Amit Mahipal, et al.
Annals of Surgical Oncology
|
May 4, 2026
Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma
Yawen Dong, Kever A Lewis, David Pereyra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
Amro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 56) with videos related to
Sort By:
Page
of 6
European Journal of Cancer (Oxford, England : 1990)
|
June 17, 2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer
Yawen Dong, David Pereyra, Vanja Podrascanin, et al.
British Journal of Cancer
|
June 4, 2026
A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms
T R Jeffry Evans, Natalie Cook, Anthony El-Khoueiry, et al.
Annals of Surgery
|
June 23, 2025
Development of the Perihilar Cholangiocarcinoma Risk Estimation of Tumor Recurrence After Transplant (PRETREAT) Score
Zhihao Li, Timucin Taner, John E Eaton, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
May 5, 2024
Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
Benjamin J Van Treeck, Maria C Olave, Ryan D Watkins, et al.
The Oncologist
|
December 14, 2024
Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience
Paulina Marell, Ioannis Kournoutas, Jennifer Gile, et al.
Investigational New Drugs
|
August 31, 2021
A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma
Daniel H Ahn, Pedro Luiz Serrano Uson Junior, Peter Masci, et al.
HPB : the Official Journal of the International Hepato Pancreato Biliary Association
|
May 24, 2024
WITHDRAWN: Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma
Benjamin J Van Treeck, Maria C Olave, Ryan D Watkins, et al.
JCO Precision Oncology
|
November 15, 2021
FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience
Jennifer J Gile, Fang-Shu Ou, Amit Mahipal, et al.
Annals of Surgical Oncology
|
May 4, 2026
Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma
Yawen Dong, Kever A Lewis, David Pereyra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma
Amro M Abdelrahman, Ajit H Goenka, Roberto Alva-Ruiz, et al.
Page
of 6